etodolac has been researched along with Colorectal Cancer in 3 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer." | 9.15 | Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. ( Hirayama, M; Kato, J; Kimura, T; Maeda, M; Mori, M; Nagashima, H; Nakano, Y; Niitsu, Y; Nojiri, S; Sato, Y; Sekikawa, H; Sonoda, T; Takahashi, Y; Takayama, T, 2011) |
| " The aim of this study was to investigate the synergistic effect of Etodolac (ET) and ionizing radiation on human colorectal cancer cells." | 8.12 | Etodolac Enhances the Radiosensitivity of Irradiated HT-29 Human Colorectal Cancer Cells. ( Abbasi, S; Albooyeh, H; Alvandi, M; Dastranj, L; Farzipour, S; Polgardani, NZ; Shaghaghi, Z, 2022) |
| "We injected colon 26, a colorectal cancer cell line, in CDF1 mouse spleen and, from the following day, two kinds of COX-2 inhibitor (etodolac and nimesulide) were administered orally." | 5.33 | Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. ( Aoki, T; Hisada, M; Ishizaki, T; Katsumata, K; Kawakita, H; Mori, Y; Tsuchida, A; Wada, T, 2006) |
| "On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer." | 5.15 | Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. ( Hirayama, M; Kato, J; Kimura, T; Maeda, M; Mori, M; Nagashima, H; Nakano, Y; Niitsu, Y; Nojiri, S; Sato, Y; Sekikawa, H; Sonoda, T; Takahashi, Y; Takayama, T, 2011) |
| " The aim of this study was to investigate the synergistic effect of Etodolac (ET) and ionizing radiation on human colorectal cancer cells." | 4.12 | Etodolac Enhances the Radiosensitivity of Irradiated HT-29 Human Colorectal Cancer Cells. ( Abbasi, S; Albooyeh, H; Alvandi, M; Dastranj, L; Farzipour, S; Polgardani, NZ; Shaghaghi, Z, 2022) |
| "We injected colon 26, a colorectal cancer cell line, in CDF1 mouse spleen and, from the following day, two kinds of COX-2 inhibitor (etodolac and nimesulide) were administered orally." | 1.33 | Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. ( Aoki, T; Hisada, M; Ishizaki, T; Katsumata, K; Kawakita, H; Mori, Y; Tsuchida, A; Wada, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shaghaghi, Z | 1 |
| Polgardani, NZ | 1 |
| Abbasi, S | 1 |
| Albooyeh, H | 1 |
| Dastranj, L | 1 |
| Farzipour, S | 1 |
| Alvandi, M | 1 |
| Takayama, T | 1 |
| Nagashima, H | 1 |
| Maeda, M | 1 |
| Nojiri, S | 1 |
| Hirayama, M | 1 |
| Nakano, Y | 1 |
| Takahashi, Y | 1 |
| Sato, Y | 1 |
| Sekikawa, H | 1 |
| Mori, M | 1 |
| Sonoda, T | 1 |
| Kimura, T | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
| Ishizaki, T | 1 |
| Katsumata, K | 1 |
| Tsuchida, A | 1 |
| Wada, T | 1 |
| Mori, Y | 1 |
| Hisada, M | 1 |
| Kawakita, H | 1 |
| Aoki, T | 1 |
1 trial available for etodolac and Colorectal Cancer
| Article | Year |
|---|---|
Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Topics: Aberrant Crypt Foci; Adenoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2011 |
2 other studies available for etodolac and Colorectal Cancer
| Article | Year |
|---|---|
Etodolac Enhances the Radiosensitivity of Irradiated HT-29 Human Colorectal Cancer Cells.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Etodolac; HT29 Cells; Humans; Radiation Tolerance | 2022 |
Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Etodol | 2006 |